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Abstract 
A simple and sensitive sensor method for cancer biomarkers [prostate specific antigen 
(PSA) and PSA-alpha 1 antichymotrypsin (ACT) complex] analysis was developed, to be 
applied directly with human serum (75%) by using antibody modified quartz crystal 
microbalance sensor and nanoparticles amplification system. A QCM sensor chip 
consisting of two sensing array enabling the measurement of an active and control 
binding events simultaneously on the sensor surface was used in this work. The 
performance of the assay and the sensor was first optimised and characterised in pure 
buffer conditions before applying to serum samples. Extensive interference to the QCM 
signal was observed upon the analysis of serum. Different buffer systems were then 
formulated and tested for the reduction of the non-specific binding of sera proteins on the 
sensor surface. A PBS buffer containing 200 µg mL
-1
 BSA, 0.5 M NaCl, 500 µg mL
-1
 
dextran and 0.5% Tween 20, was then selected which eliminated the interfering signal by 
98% and enabled the biomarker detection assay to be performed in 75% human serum.  
By using Au nanoparticles to enhance the  QCM sensor signal, a limit of detection of 0.29 
ng mL
-1
 PSA and PSA-ACT complex (in 75 % serum) with a linear dynamic detection 
range up to 150 ng mL
-1
 was obtained. With the achieved detection limit in serum 
samples, the developed QCM assay show a promising technology for cancer biomarker 
analysis in patient samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Cancer biomarkers, prostate specific antigen, PSA, human serum, biosensor, 
quartz crystal microbalance, QCM, nanoparticles, point of care assay.  
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The World Health Organisation (WHO) states that around 13% of all deaths worldwide in 
2007 were caused by cancer [1]. Early and accurate detection of cancer is very important 
before it spreads out to the other organs of the body and this makes early diagnosis very 
important for successful treatment of the disease. The detection of cancer biomarkers in 
patient samples provides an effective way to diagnose and treat the disease. Recent 
advances in the area of sensor technology and microarrays have enabled the 
miniaturisation of the devices and multiplex testing of a range of analytes. Therefore, 
biosensor technology has the potential to produce point of care cancer testing devices that 
detects biomarkers [2].  
 
Among different cancer types, prostate cancer which is a complex and multifactorial 
disease is the commonest form of cancer in men in Europe (301,500 incident cases, 
24.1% of all cancer cases) [3]. The increase in prostate specific antigen (PSA) levels in 
serum above the normal limits is the primary indication of prostate malignancy; therefore 
PSA is used as a biomarker for the diagnosis and prognosis of the prostate cancer [4; 5]. 
Several biosensor systems have been applied in the past for the detection of PSA; 
electrochemical [6; 7; 8], optical [9; 10; 11], fluorescence / chemiluminescence [12; 13], 
microcantilever [14; 15] and quartz crystal microbalance (QCM) biosensors [16; 17] were 
used for the detection.  The detection limit of PSA using these systems varies between 0.2 
pg mL
-1
 to 10 ng mL
-1
. The detection signal has been amplified by means of a sandwich 
assay with Au nanoparticles or the use of carbon nanotubes. In most cases biomarker 
detection test was performed only in buffered pure solutions rather than serum. To obtain 
clinically relevant results, it is essential to perform the biomarker test in human serum. 
The main difficulty of using serum as the assay media is high non-specific interaction 
between the sensor surface and serum proteins. A number of strategies have been 
employed to reduce the non-specific binding of clinical samples. As an example Cao et 
al. used mixed self-assembled monolayer coated surface which contains ethylene glycol 
units [9], Kurosawa et al. used 2-methacryloyloxyethyl phosphorylcholine polymer as 
blocking agent [18] and Situ et al. employed additives in the buffer to lower the non-
specific binding of serum proteins [19] to the sensor surface. The above described 
1 Introduction 
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methods can either be applied individually or together to reduce the non-specific binding 
of serum proteins achieving different success.  
 
In this paper we describe the development of a simple and rapid detection method for 
cancer biomarkers analysis using a quartz crystal microbalance (QCM) biosensor. A 
QCM consists of a thin quartz wafer sandwiched between a pair of electrodes. The mode 
of oscillation depends on the cut and geometry of the quartz crystal. Mass addition or loss 
on the sensor surface results in frequency change and hence measuring molecular 
interactions that occur on the sensor surface without the need of a label. By employing Au 
nanoparticles in the assay design, it is possible to increase the mass due to antigen binding 
and further enhance the sensitivity of the assay [20; 21]. However, the frequency is also 
affected by viscosity change of the assay media and charge of the interaction molecules 
[22]. Therefore, care needs to be taken to subtract the controls and extract the real 
response due to specific molecular interactions. The sensitivity enhancement using 
nanoparticles has been usually achieved by modifying a secondary antibody to the 
nanoparticles and performing a sandwich assay. 
 
In this work an investigation was performed to develop and optimise an immunoassay to 
detect biomarkers in human serum on the QCM sensor chip. To minimise the matrix 
effect of human serum, the addition of detergent, salt and other additives to the buffer 
solution was investigated. PSA and PSA-ACT complex were used as the cancer 
biomarkers for detection and an immunoassay was developed and performed in buffer 
and in human serum. 
 
 
PSA, monoclonal PSA detection (cat no: MCA2561) and capture antibodies (cat no: 
MCA2560) were obtained from AbD Serotec, (Kidlington, UK). ACT-PSA complex was 
purchased from BiosPacific (CA, USA). Mouse IgG (cat no: 015-000-003) usually used 
as a control antibody was obtained from Stratech Scientific Ltd./Jackson 
ImmunoResearch (Newmarket, UK). Human serum and bovine serum albumin (BSA) 
were purchased from Sigma-Aldrich (Poole, UK). All other chemicals were of analytical 
grade.  
2 Materials and Methods 
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2.1 Instrumentation 
A fully automated QCMA-1 biosensor instrument and sensor chips were obtained from 
Sierra Sensors GmbH (Hamburg, Germany). Au coated QCMA-1 sensor chips (20 MHz) 
possess two sensing arrays each, enabling the measurement of active and control sensor 
surfaces simultaneously (Figure 1S
1
). The operating temperature of the assays was 25ºC 
and the flow rate of the buffer was 80 µl min
-1
 throughout the assay. The data presented in 
this work are the averages of 4 data points for the assays described unless otherwise 
stated.  
2.2 Modification of Au nanoparticles with Anti-PSA detection antibody   
PSA detection antibody was added to the 40 nm Au nanoparticle solution and incubated 
at room temperature on a shaker. BSA was added to the solution to ensure that the Au 
nanoparticles are all coated with antibody or protein. After spinning 20 minutes at 4ºC, 
the antibody modified nanoparticles were recovered and re-suspended in PBS/T buffer. 
The concentration of nanoparticles was determined by a spectrophotometer at 520 nm 
wavelength. The antibody modified Au nanoparticles were then stored in the fridge (4
o
C) 
until use. 
2.3 Sensor surface modification 
Initially gold coated QCMA-1 sensor chips were coated with self assembled monolayer 
(SAM) by immersing the sensors in 2 mM ethanol solution of mercaptoundecanoic acid 
overnight followed by rinsing with ethanol and water and then dried under nitrogen. The 
sensors were stored at 4
o
C till use.  For the AFM (Atomic Force Microscopy) study, 
Dimension 3000 SPM instrument (Veeco Instruments Ltd., Cambridge) was used with 
silicon probes (type: PPP-NCH-50). The analysis was carried out at tapping mode. AFM 
images of QCMA-1 sensor were taken before and after surface chemistry application. For 
the assay,  the SAM coated sensor chip was first docked to the instrument and primed 
with running buffer (10 mM PBS, pH 7.4) at a flow rate of 80 µl min
-1 
until use. 
Monoclonal anti-PSA antibodies (capture antibody) and Mouse IgG antibody (control 
antibody) were then immobilised on the sample and control sensing arrays respectively 
using conventional amine coupling chemistry. Sensor surfaces were first activated with a 
                                                 
1
 Figure numbers ended with letter ‘S’ are presented at the supplementary information. 
Page 6 of 20
Ac
ce
pte
d M
an
us
cri
pt
  Development of a QCM Assay for PSA Detection 
 
6 
 
1 : 1 mixture of 400 mM EDC and 100 mM NHS by injecting simultaneously across the 
two sensing spots for 3 min (240 µl). A 15-30 or 50 µg mL
-1
 anti-PSA antibody (in 
sodium acetate buffer, 10 mM, pH 5.5) was injected on the active sensor array and 15-30 
or 50  µg mL
-1
 mouse IgG (in sodium acetate buffer, pH 5.5) was injected on the control 
sensor array for 3 min (240 µl).  The surfaces were then blocked with 50 µg mL
-1
 BSA in 
PBS for 3 min (240 µl).  Non-reacted NHS esters were capped with 1 M ethanolamine, 
pH 8.5 for 3 min (240 µl). The frequency changes were recorded 2 min after the protein 
injection was completed and the signal reached steady state. The running buffer was 
changed to PBS containing 0.005% Tween (PBS/T) for the binding assay studies. 
2.4 Detection of PSA  
In serum, PSA is found either in free form or as a complex with alpha 1-antichymotrypsin 
(ACT) (ACT-PSA, MW 96 kDA). Total PSA (tPSA) refers to the PSA in both forms 
(PSA and ACT-PSA complex). In the current study to prepare tPSA 1 to 1 mixture of 
PSA and ACT-PSA was used. PSA or tPSA was diluted at specified concentrations (0.29 
to 5000 ng mL
-1
) in PBS/T buffer containing 5 µg mL
-1
 BSA or 10% to 75% human 
serum in PBS/T buffer containing additives. These solutions were then injected over the 
PSA capture antibody and mouse IgG immobilised surfaces for 3 or 5 min to allow 
binding interactions (240 or 400 µl).  The frequency changes due to PSA/tPSA binding 
were recorded at 180 s after the injection started. After the binding of PSA/tPSA either 
surface was regenerated by injection of 100 mM HCl (1 min, 80 µl) or the assay was 
continued to perform a sandwich assay. 
 
After the binding of PSA/tPSA to the sensor surface, 1.5 µg mL
-1
 PSA detection 
antibodies or PSA detection antibody modified Au nanoparticles were injected on the 
sensor surface for 3 or 5 min (240 or 400 µl).  After 3 min dissociation period under 
running buffer flow, surfaces were regenerated by injection of 100 mM HCl (1 min, 80 
µl) (and additional 20 mM NaOH (1 min, 80 µl) was injected if PSA spiked human serum 
was used). The frequency changes due to PSA detection antibody binding were recorded 
3 min after the injection started. The limit of detection (LOD) was calculated as the signal 
obtained from the PSA concentration that is equivalent to the 3 times the standard 
deviation of the signals obtained from the blank standards. 
 
Page 7 of 20
Ac
ce
pte
d M
an
us
cri
pt
  Development of a QCM Assay for PSA Detection 
 
7 
 
 
 
3.1 Optimisation of sensor signal  
Bare gold QCMA-1 sensor chips were employed in this work as the sensor platform for 
PSA detection. Each chip consists of two sensing array for active and control sample 
testing. The modification of the chips using self assembled monolayer (SAM) was carried 
out on the sensor surface.  Atomic Force Microscopy (AFM) images of a sensor chip 
were taken before and after the SAM coating (Figure 2S). The results indicate that SAM 
modification caused a change of the root mean square (rms) roughness from 5.5 nm to 3.1 
nm due to surface coating. The SAM coated sensor chip was first docked to the QCMA-1 
instrument and primed with running buffer to wet the sensor chip and continues buffer 
flow (80 µl min
-1
) was started. Anti-PSA capture antibody and mouse IgG were then 
immobilised on the active sensor array and the control sensor array respectively using 
conventional EDC-NHS chemistry [23]. A 3 minutes injection of antibodies was 
sufficient to achieve signal saturation; therefore, the immobilisation time was kept at 3 
minutes for the assay. Three different concentrations were used for antibody 
immobilisation and from these 30 µg mL
-1
 was chosen as the optimum concentration to 
vimmobilise the antibodies.  Anti-PSA capture antibody immobilised sensors produced an 
average frequency change of 380 ± 38 Hz and mouse IgG immobilised sensors produced 
a frequency change of 520 ± 15 Hz (Figure 3S). 
 
The PSA non-specific binding (diluted in PBS/T buffer containing 5 µg mL
-1
 BSA) to the 
control sensor array was then examined by conducting binding tests.  The results show 
that the control sensor surface did not give any frequency change even if the highest 
concentration of PSA (5 µg mL
-1
) was used (Figure 1-trace e). To examine  the non-
specific binding of BSA on the PSA capture antibody immobilised surface, BSA (5 µg 
mL
-1
) was injected for 3 min and the non-specific binding of BSA to the surface was 
detected as 4 ± 1 Hz (n = 3, data not shown).  
 
For the sandwich assay procedure, anti-PSA detection antibody (3 µg mL
-1
) was injected 
in the absence of the antigen (PSA) on to the PSA capture antibody immobilised surface 
3 Results and Discussion 
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and the non-specific binding was detected as 5 ± 2 Hz (n = 3, data not shown). The non-
specific responses were subtracted from the PSA or PSA detection antibody binding data. 
3.2 Determination of kinetic constants for PSA detection assay 
The calibration curve obtained with PSA binding (3 min) to the PSA capture antibody 
immobilised surface in a concentration range between 4.7 to 5000 ng mL
-1 
is shown in 
Figure 1 and Figure 4S. PSA binding response curves were then fitted to 1:1 Langmuir 
binding model to determine the binding association and dissociation rates [24], from 
which KD value was calculated as 5.56 × 10
-10
 M and Rmax as 108 Hz (Table 1). Karlsson 
et al. calculated the affinity of PSA antibody towards PSA as 3.3 × 10
-9
 M (antibody from 
Fitzgerald Industries Int., clone M212091) [25].  Katsamba et al. calculated the affinity as 
1.1 × 10
-9
 M (antibody from Fitzgerald Industries Int., clone M612166) [26].  
 
To enhance the sensor signal and improve the sensitivity of the method, a sandwich assay 
approach was followed employing PSA detection antibody. The calibration curve was 
obtained for the sandwich assay in a concentration range between 150 to 2.3 ng mL
-1 
that 
is relevant for prostate cancer diagnosis (Figure 4S, trace b). This assay resulted in 4.7 ng 
mL
-1
 PSA as detection limit which is four folds more sensitive than the direct assay 
(Table 2). The experiments have shown that the chosen anti- PSA antibody has good 
affinity for a successful immunoassay and the sandwich assay resulted in a clinically 
relevant detection limit. Consequently experiments were performed to optimise the assay 
so that biomarker detection could be performed in human serum. 
3.3 Buffer optimisation for human serum sample analysis 
There is a significant difference in the limit of detection when buffer or clinical sample 
(serum) is used as the assay media. For example, although Cao et al. performed the PSA-
ACT detection assay using only 10% human serum; the limit of detection has changed 
from 10.2 ng mL
-1
 (in buffer) to 18.1 ng mL
-1
 (in 10% serum) [9]. This change in the 
detection limit, when clinical samples are used, is mainly due to lower signal to noise 
ratio resulting from the high non-specific binding of sera proteins/antibodies to the sensor 
surface. This is especially noticeable when label-free biosensors are employed, and this 
prevents researchers from the use of high concentrations of human serum. Therefore, 
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most analyses are conducted using concentration of human serum in the range 10 to 50 % 
[18; 19; 27].  
 
In the current study we investigated the use of additives to minimize the adsorption of 
sera proteins to the sensor surface. Initially, a 10% human serum diluted in PBS/T buffer 
was injected on the mouse IgG immobilised sensor surface. A 1490 Hz response was 
obtained from this solution and after buffer flow started, the response was reduced to 
1370 Hz (Figure 2, A-trace 1). From the results it was evident that human serum proteins 
caused a significant non-specific binding on the surface. To reduce this non-specific 
binding salt, BSA, dextran and Tween 20 were added to the buffer at varying 
concentrations. Increase the salt concentration increases the ionic strength of the solution 
and that lowers the electrostatic attraction of human serum proteins to the sensor surface. 
Therefore, high salt concentration was used to reduce proteins adsorption to the sensor 
surface. Dextran and BSA were used to help in preventing serum protein absorption. It is 
common to employ detergents to lower the non-specific protein binding; therefore the 
concentration of Tween 20 was increased in the solution [28]. These additives at varying 
concentrations were added to prepare 10% human serum and injected over the mouse IgG 
immobilised sensor surface for 3 min (Figure 2, A). The lowest non-specific binding was 
observed when the serum is diluted in additives containing PBS/T buffer that had final 
concentrations of 200 µg mL
-1
 BSA, 0.5 M salt, 500 µg mL
-1
 dextran and 0.5% Tween 20 
in solution. The response 180s after the injection of 10% human serum diluted in this 
matrix elimination buffer (matrix buffer) was found as 251 ± 18 Hz (n = 3) and after the 
buffer flow started the response was reduced to 23 ± 12 Hz (n = 3). As it can be seen from 
Figure 2, A - trace 1, the injection of human serum in PBS/T buffer resulted in a trace that 
showed a curved structure indicating the binding of sera proteins to the sensor surface and 
there was little dissociation after the injection stopped and buffer flow was started. 
Whereas when human serum diluted in the matrix buffer was injected (Figure 2, A - trace 
5), the response trace showed an instant sharp increase up to ca. 250 Hz and remained 
showing no curvature indicated that the bulk of this response was due to the use of 
additives and therefore this matrix buffer was then used for all further assays using human 
serum. Figure 2, B, shows the comparison of non-specific binding results for 10%, 40% 
and 75% human serum diluted in the matrix buffer developed in this work and injected to 
mouse IgG immobilised surface. The low non-specific binding values for these three 
concentrations of human serum (highest 91 ± 10 Hz for 75% human serum) indicated that 
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the matrix buffer was effective even for high serum concentrations. For all the 
forthcoming experiments human serum was always diluted with the matrix buffer. 
 
These results showed that by applying the matrix buffer in the assay method, a 98% 
reduction in non-specific binding of human sera proteins was achieved. If this result is 
compared to other recently published work; Situ et al. achieved 94% reduction in non-
specific binding by using CM5 (carboxymethyl dextran) surface and a formulated buffer 
together and Trevino et al. achieved 88% reduction in non-specific binding of serum by 
using another formulated buffer [19; 29].  
The PSA assay was then performed using 20 ng mL
-1
 PSA spiked in 10% and 40% 
human serum. When the results were compared with PSA assay in PBS/T buffer, it was 
seen that both direct and sandwich PSA assay results in buffer or spiked in 10% human 
serum (diluted in matrix buffer) were very close to each other and within the standard 
deviation (Figure 3, A). However, as the human serum concentration increased to 40%, 
the response from direct assay was eliminated but still there was a response from the 
injection of PSA detection antibody (sandwich assay). Although this result was lower 
than the assay in PBS/T buffer (or assay in 10% human serum) still good enough to 
perform the assay in high human serum concentrations. An example to direct and 
sandwich assay response of PSA spiked in 10% human serum is shown in Figure 3B. 
3.4 Detection of tPSA in 75% human serum 
A calibration curve was obtained for the sandwich assay in a concentration range between 
2.3 to 150 ng mL
-1 
tPSA spiked in 75% human serum. The non-specific binding of PSA 
detection antibody after the injection of 75% human serum (without spiked PSA) was 2 ± 
1 Hz, if assay performed on mouse IgG immobilised surface and 10 ± 3 Hz if assay 
performed on PSA capture antibody immobilised surface. The PSA detection antibody 
binding responses were obtained after the subtraction of the non-specific binding 
response. The detection limit obtained for this assay was 9.4 ng mL
-1
 (Figure 5 - trace a). 
However this result was not sensitive enough for PSA detection at the required levels in 
serum. To enhance the sensitivity further 40 nm Au nanoparticles were modified with 
PSA detection antibody and sandwich assay was performed to detect tPSA. The use of Au 
nanoparticles lowered the detection limit down to 0.29 ng ml
-1
 (Figure 5 – trace b), which 
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is well below the required limit of detection. Table 2, summarises the results of the assays 
in buffer and in human serum. 
 
The specificity of the tPSA interaction with the sensor surface was tested by employing a 
mouse IgG surface on the control sensor. The non-specific binding of PSA detection 
antibody modified Au nanoparticles after the injection of 75% human serum (with or 
without spiked tPSA) resulted in no response on mouse IgG immobilised surface (Figure 
4 - trace b). The binding of PSA detection antibody modified Au nanoparticles after the 
injection of 75% human serum (without spiked tPSA) resulted in 9 ± 2 Hz response on 
anti-PSA capture antibody immobilised surface, since non-specific binding on to MIgG 
surface was very low, this result was purely due to the tPSA content of the serum 
obtained from Sigma. While creating the calibration curve, this response was deducted 
from the responses obtained to get the binding results due to the spiked tPSA. Later after 
calibration curve of tPSA assay was obtained, it was calculated that serum from Sigma 
used for the study contains 0.41 ng ml
-1
 tPSA. 
 
In conclusion, the limit of detection of the biomarker assay was 0.29 ng ml
-1
 (corresponds 
to 0.39 ng ml
-1
 in 100% serum) with a linear detection range of 0.29-150 ng ml
-1
 and the 
coefficient of variation (CV) laid between 1 to 9% across the range. These results show 
that the assay developed with the formulated matrix buffer and Au nanoparticle signal 
amplification, have potential for the rapid and sensitive detection of serum biomarkers in 
patient samples. 
 
The number of publications related to the detection of PSA using QCM biosensor is very 
limited and this indicates that application of QCM biosensors to PSA detection is a newly 
developing area. An example to a previous study for PSA assay using QCM biosensor has 
been the study performed by Zhang et al. which involve the use of an insert-plug model 
of piezoelectric immunosensor. After 40 min of reaction at 37ºC in a static cell with a 10 
MHz quartz crystal, Zhang et al achieved linear detection of 1.5 – 40 ng mL-1 PSA in 
100% serum [17]. Although the detection limit obtained from this study was low enough, 
the reaction time was long and assay needs to be performed at elevated temperatures. 
Additionally the dynamic range of the assay was limited. In another study, Ding et al. 
used yeast cell modified QCM sensors to immobilise PSA antibodies [16]. The binding of 
PSA to the PSA antibody immobilised sensor was recorded after the binding reached 
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equilibrium using a 9 MHz quartz crystal and magnetic stirrer agitated static cell. With 
this method Ding et al. achieved detection of PSA in the range of 5 to 604 ng mL
-1
 in 
100% serum. Both applications mentioned above were performed using non-automated 
equipment that due to their manual operation may not only cause variations between the 
assays but also are not suitable for clinicians use. In another study Cao et al. performed 
10 min PSA-ACT assay in 10 % human serum using an automated SPR biosensor and 
obtained a detection limit of 18.1 ng mL
-1
 that corresponds to LOD of 181 ng mL
-1
for the 
whole serum [9].  
 
In our study although 75% serum was used as assay matrix, the detection limit obtained 
was 0.29 ng mL
-1
 for a 8 min assay which corresponds to 0.39 ng mL
-1
 tPSA in the whole 
serum indicating the good performance of the optimised assay. Additionally; although 
high concentration of serum was used for the assay, matrix buffer limited the non-specific 
binding of the proteins on to sensor spots and allowed complete regeneration of the sensor 
surface by short injections of 100 mM HCl and 20 mM NaOH. This enables the repeated 
use of the same sensor chip for several times to analyse multiple serum samples to detect 
tPSA. 
 
The experimental conditions reported in the literature vary between the assays 
significantly such as, assays in static or in flow, temperature, assay time and the antibody 
used against PSA. All these contribute to the assay sensitivity and hence make it difficult 
to compare the results effectively. When compared briefly to similar label-free PSA 
assays such as above, the assay developed in this study, with total 8 min reaction time, 
repeated usability and LOD of 0.29 ng mL
-1
 in 75% human serum, proves the advantage 
of the optimised assay format suitable for point of care system. Additionally due to it is 
being rapid and wide detection range the QCM assay developed outperforms the 
commercial ELISA kits available for biomarker detection (Table 3).  
 
 
Early diagnosis of cancer biomarkers is essential for successful treatment of the disease. 
The current biomarker tests are ELISA type and usually performed at centralised labs 
using automated devices. In this work, a groundwork study was described for the use of 
QCM biosensor to perform cancer biomarker detection test. A new buffer was formulated 
to eliminate 98% of the non-specific human serum protein binding to the sensor surface. 
4 Conclusion 
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A sandwich assay using QCMA-1 affinity sensor chips resulted in detection of tPSA 
concentrations as low as 0.29 ng mL
-1
 in 75% human serum.
 
Short assay time, repeated 
usability of the same sensor chip, ability to detect PSA in high serum concentrations and 
utilisation of a label-free detection method enables the optimised assay format a 
promising tool for clinical diagnosis/prognosis.  
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Figure 4. 
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Figure 5. 
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Table 1. Results of kinetic calculations for PSA direct assay. 
 
KD  = 5.56 × 10
-10
 M 
Ka = 1.23 × 10
+06
 M
-1 
s
-1 
Kd = 6.83 × 10
-04
 s
-1 
Rmax =  108 Hz 
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Table 2. The summary of the PSA detection assay results. 
 
  
direct assay in 
PBS/T 
sandwich assay 
in PBS/T 
sandwich assay 
in 75% serum 
sandwich assay in 
75% serum using Au 
nanoparticles 
LOD  18.8 ng mL
-1
 4.7 ng mL
-1
 9.4 ng mL
-1
 0.29 ng mL
-1
 
Linear range 18.8 – 150 ng mL-1 4.7 – 150 ng mL-1 9.4 – 150 ng mL-1 0.29  – 150 ng mL-1 
 Equation 
y = 0.87x + 0.27 
(R
2
 = 1.00)* 
y = 0.91x + 0.35 
 (R
2
 = 0.99)* 
y = 0.89x + 0.33 
 (R
2
 = 0.98)* 
y = 71.96Ln(x)+73.77 
(R
2
 = 0.99) 
*y = log (response); x = log (concentration) 
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Table 3. The summary of the PSA detection limit and detection ranges for some of the 
commercial ELISA kits and the developed QCM assay. 
 
 
Detection range 
(ng mL
-1
) 
Limit of detection 
(ng mL
-1
) 
The developed QCM assay*  0.39 – 200 0.39 
Abazyme PSA ELISA kit 1 - 80 1 
MP Biomedicals PSA ELISA kit 2 - 120 1 
Alpco Diagnostics PSA ELISA kit 2 - 120 1 
Calbiotech PSA ELISA kit 0.585 - 50 0.585 
Alpha Diagnostic PSA ELISA kit 0.3-60 0.30 
*Both detection range and limit is given based on 100% serum. 
 
